Stockreport

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage [Financial Post (Toronto, O...

Acasti Pharma, Inc. - Class A  (ACST) 
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors
PDF Article content LAVAL, Québec, Sept. 27, 2021 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the in [Read more]